No Data
No Data
Merrimack Pharmaceuticals (MACK.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -0.03 dollars, previous value of -0.02 dollars.
Merrimack Pharmaceuticals (MACK.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -0.03 dollars, previous value of -0.02 dollars.
Merrimack Pharmaceuticals | 10-Q: Quarterly report
Vicore Expands and Strengthens Its Board of Directors
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
Merrimack Pharmaceuticals To Go Ex-Dividend On May 20th, 2024 With 15.1 USD Dividend Per Share
May 14th - $Merrimack Pharmaceuticals(MACK.US)$ is trading ex-dividend on May 20th, 2024. Shareholders of record on May 10th, 2024 will receive 15.1 USD dividend per share on May 17th, 2024. The e
Merrimack Pharmaceuticals Shareholders OK Dissolution Plan
By Ben Glickman Merrimack Pharmaceuticals said Friday that its shareholders had approved its plan of dissolution and an accompanying liquidating cash dividend. The dividend will be $15.10 a share, e
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that